• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性髓性白血病中BCR-ABL酪氨酸激酶抑制剂的心血管毒性：预防策略与心血管监测

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.

作者信息

Aghel Nazanin, Delgado Diego Hernan, Lipton Jeffrey Howard

机构信息

Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network,University of Toronto.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.

出版信息

Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017.

DOI:10.2147/VHRM.S108874
PMID:28831263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5552150/
Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular safety of TKIs are discussed. We also propose management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents.

摘要

酪氨酸激酶抑制剂（TKIs）彻底改变了慢性髓性白血病（CML）的治疗方法和治疗效果。尽管它们对CML的管理产生了重大影响，但越来越多的证据表明，TKIs可能会导致心血管和/或代谢并发症。在本综述中，我们介绍了关于BCR-ABL TKIs心血管安全性的现有证据。讨论了报告TKIs心血管安全性的研究在方法学上所面临的挑战。我们还提出了在使用这些药物治疗期间进行心血管监测和危险因素修正的管理策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/5552150/8cc351ecbe4e/vhrm-13-293Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/5552150/8cc351ecbe4e/vhrm-13-293Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d9/5552150/8cc351ecbe4e/vhrm-13-293Fig1.jpg

相似文献

1
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.慢性髓性白血病中BCR-ABL酪氨酸激酶抑制剂的心血管毒性：预防策略与心血管监测
Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017.
2
Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.BCR-ABL1 酪氨酸激酶抑制剂在慢性髓性白血病中心血管毒性的作用机制。
Curr Hematol Malig Rep. 2020 Feb;15(1):20-30. doi: 10.1007/s11899-020-00560-x.
3
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.达沙替尼与尼洛替尼治疗慢性髓性白血病慢性期的比较：一项网状荟萃分析
Acta Haematol. 2020;143(3):217-231. doi: 10.1159/000501927. Epub 2019 Oct 7.
4
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.酪氨酸激酶抑制剂治疗慢性髓性白血病患者的协同心血管管理。
Vasc Med. 2020 Jun;25(3):246-254. doi: 10.1177/1358863X20906868. Epub 2020 Apr 17.
5
[Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].[酪氨酸激酶抑制剂相关的慢性髓性白血病心血管不良事件]
Rinsho Ketsueki. 2021;62(8):1024-1028. doi: 10.11406/rinketsu.62.1024.
6
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.慢性髓性白血病的分子监测与突变：如何充分利用酪氨酸激酶抑制剂
Am Soc Clin Oncol Educ Book. 2014:167-75. doi: 10.14694/EdBook_AM.2014.34.167.
7
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.BCR-ABL 酪氨酸激酶抑制剂在慢性髓性白血病中的作用谱。
Int J Hematol. 2021 May;113(5):632-641. doi: 10.1007/s12185-021-03126-6. Epub 2021 Mar 27.
8
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.BCR-ABL TKIs 耐药机制及治疗策略：综述。
Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13.
9
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.酪氨酸激酶抑制剂相关的慢性髓性白血病心血管毒性
J Clin Oncol. 2015 Dec 10;33(35):4210-8. doi: 10.1200/JCO.2015.62.4718. Epub 2015 Sep 14.
10
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.BCR-ABL 酪氨酸激酶抑制剂治疗费城染色体阳性慢性髓性白血病：综述。
Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016.

引用本文的文献

1
Toxicity assessment of imatinib mesylate and a related impurity: in vitro and in vivo approaches.甲磺酸伊马替尼及一种相关杂质的毒性评估：体内外研究方法
Toxicol Res (Camb). 2025 Feb 26;14(1):tfaf029. doi: 10.1093/toxres/tfaf029. eCollection 2025 Feb.
2
Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.揭示心脏毒性之谜：探索酪氨酸激酶抑制剂治疗的海洋。
Cancer Control. 2024 Jan-Dec;31:10732748241285755. doi: 10.1177/10732748241285755.
3
Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus.

本文引用的文献

1
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
2
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.达沙替尼治疗的慢性期慢性髓性白血病患者的胸腔积液：识别与管理
Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):78-82. doi: 10.1016/j.clml.2016.09.012. Epub 2016 Sep 17.
3
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
儿童肿瘤患者的心脏肿瘤学建议：澳大利亚和新西兰德尔菲共识
JACC Adv. 2022 Dec 30;1(5):100155. doi: 10.1016/j.jacadv.2022.100155. eCollection 2022 Dec.
4
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.阿西替尼单药治疗 T315I 突变的慢性期慢性髓性白血病患者：≥1 种既往酪氨酸激酶抑制剂治疗后的 2 年随访结果。
Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16.
5
Prophylactic treatment with the c-Abl inhibitor, neurotinib, diminishes neuronal damage and the convulsive state in pilocarpine-induced mice.预防性使用 c-Abl 抑制剂神经妥乐平可减轻匹罗卡品诱导的小鼠神经元损伤和惊厥状态。
Cell Rep. 2024 May 28;43(5):114144. doi: 10.1016/j.celrep.2024.114144. Epub 2024 Apr 23.
6
Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics.口服肿瘤治疗药物引起心血管不良事件的心脏肿瘤干预的真实世界数据。
Cardiooncology. 2024 Apr 9;10(1):22. doi: 10.1186/s40959-024-00221-5.
7
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.酪氨酸激酶抑制剂在慢性髓性白血病中的心血管不良事件：临床相关性、对预后的影响、预防措施及治疗策略
Curr Treat Options Oncol. 2023 Dec;24(12):1720-1738. doi: 10.1007/s11864-023-01149-1. Epub 2023 Dec 4.
8
Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy.结直肠癌药物治疗相关心血管毒性的最新观点
Pharmaceuticals (Basel). 2023 Oct 11;16(10):1441. doi: 10.3390/ph16101441.
9
The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.小分子靶向 BCR-ABL 在慢性髓性白血病治疗中的进展。
Mini Rev Med Chem. 2024;24(6):642-663. doi: 10.2174/0113895575218335230926070130.
10
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.阿伐替尼治疗费城染色体阳性慢性髓性白血病：聚焦患者选择与治疗结果
Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023.
2016年美国心脏协会/美国心脏病学会下肢外周动脉疾病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2017 Mar 21;69(11):e71-e126. doi: 10.1016/j.jacc.2016.11.007.
4
Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline.尼洛替尼一线治疗慢性期慢性髓性白血病患者的心血管效应在随访期间的基线和监测的个体化分层建议。
Crit Rev Oncol Hematol. 2016 Nov;107:190-198. doi: 10.1016/j.critrevonc.2016.10.002. Epub 2016 Oct 15.
5
Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.小分子酪氨酸激酶抑制剂的心血管毒性：基于系统方法的机遇
Clin Pharmacol Ther. 2017 Jan;101(1):65-80. doi: 10.1002/cpt.552. Epub 2016 Nov 26.
6
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.阿司匹林在糖尿病患者一级心血管风险预防中的应用及其他作用。
Circulation. 2016 Nov 15;134(20):1579-1594. doi: 10.1161/CIRCULATIONAHA.116.023164. Epub 2016 Oct 11.
7
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.《2016年加拿大心血管学会成人血脂异常管理预防心血管疾病指南》
Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 25.
8
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.对可能使用波纳替尼的慢性髓性白血病患者心血管风险的识别、预防及管理：专家意见
Ann Hematol. 2017 Apr;96(4):549-558. doi: 10.1007/s00277-016-2820-x. Epub 2016 Sep 30.
9
Ponatinib in the therapy of chronic myeloid leukemia.帕纳替尼治疗慢性髓性白血病。
Expert Rev Hematol. 2016 Oct;9(10):923-32. doi: 10.1080/17474086.2016.1232163.
10
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).2016年欧洲心脏病学会（ESC）实践指南委员会主持制定的关于癌症治疗与心血管毒性的立场文件：欧洲心脏病学会（ESC）癌症治疗与心血管毒性特别工作组。
Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26.